HRP20020198B1 - Formulacija moksifloksacina i kuhinjske soli - Google Patents

Formulacija moksifloksacina i kuhinjske soli

Info

Publication number
HRP20020198B1
HRP20020198B1 HR20020198A HRP20020198A HRP20020198B1 HR P20020198 B1 HRP20020198 B1 HR P20020198B1 HR 20020198 A HR20020198 A HR 20020198A HR P20020198 A HRP20020198 A HR P20020198A HR P20020198 B1 HRP20020198 B1 HR P20020198B1
Authority
HR
Croatia
Prior art keywords
kitchen
salts
moxifloxacin
moxifloxacin formulation
formulation
Prior art date
Application number
HR20020198A
Other languages
English (en)
Croatian (hr)
Inventor
K�hn Bernd
Friedrich Mahler Hans
Eisele Michael
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7917417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020198(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of HRP20020198A2 publication Critical patent/HRP20020198A2/hr
Publication of HRP20020198B1 publication Critical patent/HRP20020198B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20020198A 1999-08-06 2000-07-25 Formulacija moksifloksacina i kuhinjske soli HRP20020198B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937116A DE19937116A1 (de) 1999-08-06 1999-08-06 Moxifloxacin Kochsalzformulierung
PCT/EP2000/007098 WO2001010465A1 (de) 1999-08-06 2000-07-25 Moxifloxacin kochsalzformulierung

Publications (2)

Publication Number Publication Date
HRP20020198A2 HRP20020198A2 (en) 2004-02-29
HRP20020198B1 true HRP20020198B1 (hr) 2011-02-28

Family

ID=7917417

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020198A HRP20020198B1 (hr) 1999-08-06 2000-07-25 Formulacija moksifloksacina i kuhinjske soli

Country Status (40)

Country Link
US (1) US6548079B1 (https=)
EP (1) EP1206281B1 (https=)
JP (1) JP5522877B2 (https=)
KR (1) KR100735788B1 (https=)
CN (1) CN1246039C (https=)
AR (1) AR025001A1 (https=)
AT (1) ATE270104T1 (https=)
AU (1) AU771058B2 (https=)
BG (1) BG65304B1 (https=)
BR (1) BRPI0013010B8 (https=)
CA (1) CA2378424C (https=)
CO (1) CO5190677A1 (https=)
CU (1) CU23367A3 (https=)
CZ (1) CZ298768B6 (https=)
DE (2) DE19937116A1 (https=)
DK (1) DK1206281T3 (https=)
EE (1) EE04771B1 (https=)
ES (1) ES2223549T3 (https=)
GT (1) GT200000123A (https=)
HK (1) HK1049615B (https=)
HN (1) HN2000000115A (https=)
HR (1) HRP20020198B1 (https=)
HU (1) HU229571B1 (https=)
IL (2) IL147553A0 (https=)
MA (1) MA25427A1 (https=)
MX (1) MXPA02001254A (https=)
MY (1) MY125356A (https=)
NO (1) NO320743B1 (https=)
NZ (1) NZ516969A (https=)
PE (1) PE20010400A1 (https=)
PL (1) PL198132B1 (https=)
PT (1) PT1206281E (https=)
RU (1) RU2260429C9 (https=)
SI (1) SI1206281T1 (https=)
SK (1) SK285650B6 (https=)
TW (1) TWI238719B (https=)
UA (1) UA72268C2 (https=)
UY (1) UY26269A1 (https=)
WO (1) WO2001010465A1 (https=)
ZA (1) ZA200200215B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE10218328A1 (de) 2002-03-05 2003-09-25 Humboldt Uni Zu Berlin Medizin Mittel zur präventiven Therapie nach akutem Schlaganfall
US20040197408A1 (en) * 2002-12-30 2004-10-07 Angiotech International Ag Amino acids in micelle preparation
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
DE102006031175A1 (de) * 2006-07-06 2008-01-10 Bayer Healthcare Ag Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
US7537532B2 (en) * 2007-05-16 2009-05-26 Young Carl D Handle for implement and method
CN101787022B (zh) * 2009-10-09 2012-08-22 浙江医药股份有限公司新昌制药厂 一种喹啉羧酸盐酸盐一水合物晶型及其制备方法
WO2011086577A2 (en) * 2010-01-12 2011-07-21 Msn Laboratories Limited Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
CN101836950A (zh) * 2010-03-12 2010-09-22 陕西合成药业有限公司 一种盐酸莫西沙星葡萄糖注射液及其制备方法和用途
CN101972257B (zh) * 2010-09-10 2015-08-05 杭州民生药业有限公司 一种含有莫西沙星的药物组合物
CN102100666B (zh) * 2011-01-17 2012-07-18 南京新港医药有限公司 一种新的盐酸莫西沙星注射剂
CN102093349B (zh) * 2011-01-17 2012-03-07 南京新港医药有限公司 一种工业化生产盐酸莫西沙星的方法
CN102688183B (zh) * 2011-03-21 2016-04-06 重庆医药工业研究院有限责任公司 一种稳定的盐酸莫西沙星注射剂
KR101435244B1 (ko) * 2011-04-12 2014-08-29 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
KR101327904B1 (ko) * 2011-08-16 2013-11-13 대한약품공업 주식회사 목시플록사신 염산염의 주사제형
RU2472507C1 (ru) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Водный состав на основе моксифлоксацина для парентерального введения
CN102600093B (zh) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 一种莫西沙星片剂及其制备方法
GR1008168B (el) 2013-03-14 2014-04-08 "Φαρματεν Α.Β.Ε.Ε.", Παρεντερικο σκευασμα αντιβακτηριακου παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου
CN103191056B (zh) * 2013-04-28 2014-10-22 南京海融医药科技有限公司 莫西沙星的口服液体制剂及其制备方法和应用
WO2015093669A1 (ko) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
CN103976944A (zh) * 2014-05-16 2014-08-13 成都青山利康药业有限公司 一种盐酸莫西沙星氯化钠注射液
CN104771359A (zh) * 2015-04-02 2015-07-15 南京正大天晴制药有限公司 一种稳定的盐酸莫西沙星注射液
CN105640876B (zh) * 2016-01-07 2019-04-12 天津红日药业股份有限公司 一种盐酸莫西沙星氯化钠注射液的制备工艺
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3578182A1 (en) * 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations containing triazinones and iron with a low amount of free iron ions
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
CN111388415A (zh) * 2020-03-19 2020-07-10 石家庄四药有限公司 一种盐酸莫西沙星氯化钠注射液及其制备方法
CN116490211A (zh) 2020-10-29 2023-07-25 株式会社泰俊制药 眼用组合物
CN115944586B (zh) * 2023-01-17 2024-12-17 江苏睿实生物科技有限公司 一种盐酸莫西沙星制剂的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018386A2 (en) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH01258620A (ja) * 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd 耳疾患用局所製剤
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
EP0470252A4 (en) * 1989-04-28 1992-12-02 Daiichi Pharmaceutical Co., Ltd. Anti-hiv drug
AU647772B2 (en) 1989-12-29 1994-03-31 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
US5084276A (en) 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
FR2681863B1 (fr) 1991-09-27 1995-02-03 Rhone Dpc Europ Solution de sparfloxacine sa preparation et sel la constituant.
DE4306417A1 (de) * 1993-03-02 1994-09-08 Grace Gmbh Vorrichtung und Verfahren zum Verbrennen oxidierbarer Bestandteile in einem zu reinigenden Trägergas
CA2152828A1 (en) * 1993-03-16 1994-07-07 Shin-Ichi Uesato 8-methoxy-quinolonecarboxylic acid derivatives
KR960000223A (ko) 1994-06-08 1996-01-25 김정순 신규한 피리돈 카르복실산 화합물을 함유한 수용액 및 이의 제조방법
CZ293747B6 (cs) * 1995-12-21 2004-07-14 Pfizer Inc. Vodný farmaceutický roztok vhodný pro injekční podávání hostiteli a jeho použití
JPH1192375A (ja) * 1997-09-25 1999-04-06 Morinaga Milk Ind Co Ltd ニューキノロン系抗菌剤の抗菌性を増強させる抗菌剤
TR200101310T2 (tr) * 1998-11-10 2001-10-22 Bayer Aktiengesellschaft Farmasötik moksifloksasin preparatı.
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018386A2 (en) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose

Also Published As

Publication number Publication date
JP5522877B2 (ja) 2014-06-18
ES2223549T3 (es) 2005-03-01
JP2003506416A (ja) 2003-02-18
KR100735788B1 (ko) 2007-07-06
RU2260429C2 (ru) 2005-09-20
KR20020022794A (ko) 2002-03-27
AU6159600A (en) 2001-03-05
CU23367A3 (es) 2009-04-14
RU2260429C9 (ru) 2006-03-27
HK1049615A1 (en) 2003-05-23
CO5190677A1 (es) 2002-08-29
NO20020526L (no) 2002-02-01
HK1049615B (zh) 2006-11-10
PL198132B1 (pl) 2008-05-30
HN2000000115A (es) 2001-02-02
NO320743B1 (no) 2006-01-23
UA72268C2 (uk) 2005-02-15
UY26269A1 (es) 2001-03-16
NZ516969A (en) 2004-03-26
DK1206281T3 (da) 2004-10-25
CN1246039C (zh) 2006-03-22
CA2378424A1 (en) 2001-02-15
EP1206281B1 (de) 2004-06-30
ATE270104T1 (de) 2004-07-15
MXPA02001254A (es) 2002-08-12
BG106366A (en) 2002-08-30
PT1206281E (pt) 2004-10-29
NO20020526D0 (no) 2002-02-01
CA2378424C (en) 2009-02-17
US6548079B1 (en) 2003-04-15
CZ2002458A3 (cs) 2002-06-12
MA25427A1 (fr) 2002-04-01
BR0013010B1 (pt) 2013-12-10
BG65304B1 (bg) 2008-01-31
MY125356A (en) 2006-07-31
TWI238719B (en) 2005-09-01
HUP0203619A2 (hu) 2003-02-28
AR025001A1 (es) 2002-11-06
EE04771B1 (et) 2007-02-15
ZA200200215B (en) 2002-09-25
AU771058B2 (en) 2004-03-11
EE200200060A (et) 2003-04-15
SK1682002A3 (en) 2002-06-04
PL353405A1 (en) 2003-11-17
HUP0203619A3 (en) 2003-12-29
BR0013010A (pt) 2002-04-30
DE50006974D1 (de) 2004-08-05
CZ298768B6 (cs) 2008-01-23
CN1368891A (zh) 2002-09-11
SK285650B6 (sk) 2007-05-03
IL147553A0 (en) 2002-08-14
WO2001010465A1 (de) 2001-02-15
DE19937116A1 (de) 2001-02-08
IL147553A (en) 2006-09-05
EP1206281A1 (de) 2002-05-22
SI1206281T1 (en) 2004-12-31
BRPI0013010B8 (pt) 2021-05-25
HU229571B1 (en) 2014-02-28
HRP20020198A2 (en) 2004-02-29
GT200000123A (es) 2000-08-01
PE20010400A1 (es) 2001-06-11

Similar Documents

Publication Publication Date Title
HRP20020198B1 (hr) Formulacija moksifloksacina i kuhinjske soli
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DK1200418T3 (da) Nematodicide trifluorbutener
HRP20020306B1 (en) 6-position substituted indole, production and use thereof as a medicament
EA200100678A1 (ru) N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов
HRP20020880B1 (en) New pharmaceutical composition
SE9504661D0 (sv) New compounds
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
SE9802208D0 (sv) Novel compounds
GB9514518D0 (en) Guanidine salt inhibitors of NO synthase and cyclooxygenase
BG105257A (en) New oral formulation for 5-ht4 agonists or antagonists
HRP20010878B1 (en) Ziprasidone suspension
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
HRP20010764B1 (hr) Oralna otopina s prukalopridom
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
SE9504662D0 (sv) New compounds
EP1219296A4 (en) MEANS TO INHIBIT SEBUM PRODUCTION
YU87501A (sh) Farmaceutski kompleksi
ATE299027T1 (de) Verwendung von übersulfatierten polysacchariden als hiv-hemmer
HRP20080108T3 (hr) Farmaceutski pripravci zasnovani na solima idazoksana ili na jednom od njegovih polimorfa
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
FR2820423B1 (fr) Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: BAYER HEALTHCARE AG, DE

PPPP Transfer of rights

Owner name: BAYER ANIMAL HEALTH GMBH, DE

PPPP Transfer of rights

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: BAYER PHARMA AG, DE

PPPP Transfer of rights

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190703

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200725